Journal
CELL DEATH & DISEASE
Volume 11, Issue 2, Pages -Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/s41419-020-2276-8
Keywords
-
Categories
Funding
- National Natural Science Foundation of China [81771722, 81770746]
- National Key R&D Program of China [2018YFA0107502]
- Shanghai Rising-Star Program
- Medical and Health Talents Training Plan for the Excellent Youth of Shanghai Municipal [2018YQ50]
Ask authors/readers for more resources
Erythropoietin (EPO) is an evolutionarily conserved hormone well documented for its erythropoietic role via binding the homodimeric EPO receptor (EPOR)(2). In past decades, evidence has proved that EPO acts far beyond erythropoiesis. By binding the tissue-protective receptor (TPR), EPO suppresses proinflammatory cytokines, protects cells from apoptosis and promotes wound healing. Very recently, new data revealed that TPR is widely expressed on a variety of immune cells, and EPO could directly modulate their activation, differentiation and function. Notably, nonerythropoietic EPO derivatives, which mimic the structure of helix B within EPO, specifically bind TPR and show great potency in tissue protection and immune regulation. These small peptides prevent the cardiovascular side effects of EPO and are promising as clinical drugs. This review briefly introduces the receptors and tissue-protective effects of EPO and its derivatives and highlights their immunomodulatory functions and application prospects.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available